Keapstone Therapeutics' Unattributed - II Round

Keapstone Therapeutics raised a round of funding on September 26, 2018. Investors include Parkinson's Disease Society of the United Kingdom.

Keapstone Therapeutics is developing a series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS).…

Articles about Keapstone Therapeutics' Unattributed - II Round: